163 related articles for article (PubMed ID: 21157203)
1. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
[TBL] [Abstract][Full Text] [Related]
2. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.
Wong KK; Cahill JM; Frey KA; Avram AM
Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915
[TBL] [Abstract][Full Text] [Related]
3. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
4. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
6. SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement.
Apostolova I; Riethdorf S; Buchert R; Derlin T; Brenner W; Mester J; Klutmann S
Ann Nucl Med; 2010 Jul; 24(6):477-83. PubMed ID: 20449694
[TBL] [Abstract][Full Text] [Related]
7. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
9. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
10. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J
Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
[TBL] [Abstract][Full Text] [Related]
11. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741
[TBL] [Abstract][Full Text] [Related]
12. Reconstruction parameters for 111In-pentetreotide SPECT: variability with respect to body weight and body region.
Massaro A; Cittadin S; Rossi F; Rampin L; Banti E; Nibale O; Rubello D
J Nucl Med Technol; 2007 Dec; 35(4):237-41. PubMed ID: 18006596
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a Correction Method for
Kanzaki T; Takahashi Y; Higuchi T; Zhang X; Mogi N; Suto T; Tsushima Y
J Nucl Med Technol; 2020 Dec; 48(4):326-330. PubMed ID: 32887762
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors.
Spanu A; Solinas ME; Farris A; Arru A; Chessa F; Madeddu G; Falchi A; Madeddu G
Radiol Med; 2004; 107(1-2):113-27. PubMed ID: 15031703
[TBL] [Abstract][Full Text] [Related]
15. Synchronous ileocecal neuroendocrine tumor and carotid chemodectoma: diagnosis by 111In pentetreotide SPECT/CT.
Wisotzki C; Jacobsen F; Salamon J; Derlin T
Clin Nucl Med; 2014 Jun; 39(6):547-8. PubMed ID: 24097001
[TBL] [Abstract][Full Text] [Related]
16. Differential diagnostic value of single-photon emission computed tomography/spiral computed tomography with Tc-99m-methylene diphosphonate in patients with spinal lesions.
Zhang Y; Shi H; Gu Y; Xiu Y; Li B; Zhu W; Chen S; Yu H
Nucl Med Commun; 2011 Dec; 32(12):1194-200. PubMed ID: 21934544
[TBL] [Abstract][Full Text] [Related]
17. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
18. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours.
Hillel PG; van Beek EJ; Taylor C; Lorenz E; Bax ND; Prakash V; Tindale WB
Clin Radiol; 2006 Jul; 61(7):579-87. PubMed ID: 16784943
[TBL] [Abstract][Full Text] [Related]
19. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT.
Al-Chalabi H; Cook A; Ellis C; Patel CN; Scarsbrook AF
Clin Radiol; 2018 Jun; 73(6):527-534. PubMed ID: 29397911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]